BeOne Medicines Says Its Experimental Cancer Therapies Showed 'Promising' Results at ASCO 2026

MT Newswires Live

06/01

BeOne Medicines (ONC) said Monday that new data presented at the 2026 American Society of Clinical Oncology meeting showed encouraging activity across its breast, ovarian and liver cancer programs.

The company reported that its CDK4 inhibitor BGC-43395 achieved confirmed response rates of up to 68.4% in first-line HR-positive, HER2-negative metastatic breast cancer, supporting the start of a phase 3 trial.

Its B7-H4-targeting antibody-drug conjugate BG-C9074 produced a confirmed overall response rate of 45.5% in ovarian cancer patients, while bispecific antibody BGB-B2033 delivered confirmed response rates of 28.9% in heavily pretreated hepatocellular carcinoma patients.

BeOne said the results support plans to advance several solid tumor candidates into pivotal-stage development during 2026.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2640955081"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2640955081\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2640955081?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 19:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640955081","market":"nz","top_or_hot":-1,"title":"BeOne Medicines Says Its Experimental Cancer Therapies Showed 'Promising' Results at ASCO 2026","media":"MT Newswires Live","content":"<html><body><p> BeOne Medicines (ONC) said Monday that new data presented at the 2026 American Society of Clinical Oncology meeting showed encouraging activity across its breast, ovarian and liver cancer programs.</p><p>The company reported that its CDK4 inhibitor BGC-43395 achieved confirmed response rates of up to 68.4% in first-line HR-positive, HER2-negative metastatic breast cancer, supporting the start of a phase 3 trial.</p><p>Its B7-H4-targeting antibody-drug conjugate BG-C9074 produced a confirmed overall response rate of 45.5% in ovarian cancer patients, while bispecific antibody BGB-B2033 delivered confirmed response rates of 28.9% in heavily pretreated hepatocellular carcinoma patients.</p><p>BeOne said the results support plans to advance several solid tumor candidates into pivotal-stage development during 2026.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BeOne Medicines Says Its Experimental Cancer Therapies Showed 'Promising' Results at ASCO 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeOne Medicines Says Its Experimental Cancer Therapies Showed 'Promising' Results at ASCO 2026\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-06-01 19:10</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> BeOne Medicines (ONC) said Monday that new data presented at the 2026 American Society of Clinical Oncology meeting showed encouraging activity across its breast, ovarian and liver cancer programs.</p><p>The company reported that its CDK4 inhibitor BGC-43395 achieved confirmed response rates of up to 68.4% in first-line HR-positive, HER2-negative metastatic breast cancer, supporting the start of a phase 3 trial.</p><p>Its B7-H4-targeting antibody-drug conjugate BG-C9074 produced a confirmed overall response rate of 45.5% in ovarian cancer patients, while bispecific antibody BGB-B2033 delivered confirmed response rates of 28.9% in heavily pretreated hepatocellular carcinoma patients.</p><p>BeOne said the results support plans to advance several solid tumor candidates into pivotal-stage development during 2026.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ONC","symbol_name":"百濟神州","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2640955081","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640955081","pubTimestamp":1780312221,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"BeOne Medicines  said Monday that new data presented at the 2026 American Society of Clinical Oncology meeting showed encouraging activity across its breast, ovarian and liver cancer programs.The company reported that its CDK4 inhibitor BGC-43395 achieved confirmed response rates of up to 68.4% in first-line HR-positive, HER2-negative metastatic breast cancer, supporting the start of a phase 3 trial.Its B7-H4-targeting antibody-drug conjugate BG-C9074 produced a confirmed overall response rate of 45.5% in ovarian cancer patients, while bispecific antibody BGB-B2033 delivered confirmed response rates of 28.9% in heavily pretreated hepatocellular carcinoma patients.BeOne said the results support plans to advance several solid tumor candidates into pivotal-stage development during 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ONC":"百济神州","BK4588":"碎股","BK4526":"热门中概股","BK4585":"ETF&股票定投概念","MDCO":"麦迪逊医药","BK4139":"生物科技"},"translate_title":"BeOne Medicines表示其实验性癌症疗法在ASCO 2026上显示出“有希望”的结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDCO":1.5,"ONC":1},"content_text":"BeOne Medicines (ONC) said Monday that new data presented at the 2026 American Society of Clinical Oncology meeting showed encouraging activity across its breast, ovarian and liver cancer programs.The company reported that its CDK4 inhibitor BGC-43395 achieved confirmed response rates of up to 68.4% in first-line HR-positive, HER2-negative metastatic breast cancer, supporting the start of a phase 3 trial.Its B7-H4-targeting antibody-drug conjugate BG-C9074 produced a confirmed overall response rate of 45.5% in ovarian cancer patients, while bispecific antibody BGB-B2033 delivered confirmed response rates of 28.9% in heavily pretreated hepatocellular carcinoma patients.BeOne said the results support plans to advance several solid tumor candidates into pivotal-stage development during 2026.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}